A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma

Overview of attention for article published in Frontiers in oncology, July 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 3 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,562 followers.

CAR-T cell therapy as a second line treatment appears to be effective in achieving higher response rates and delaying the disease progression compared to SOC in relapsing/remitting DLBCL https://t.co/uCm1lBCpAI

23 Jul 2024

Reply Repost Favourite

New Research: A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma https://t.co/yaMiKFOok9 #FrontiersIn #Oncology

18 Jul 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.